Table 4.
Clinical characteristics of subjects stratified by CYP2C19*2 and *3 loss-of-function alleles
| Clinical characteristics | Extensive metabolizer (n = 1,216) | Intermediate metabolizer (n = 1,399) | Poor metabolizer (n = 367) | P values |
|---|---|---|---|---|
| Age, years | ||||
| < 60, n(%) | 323(26.6) | 321(22.9) | 62(16.9) | < 0.001 |
| ≥ 60, n(%) | 893(73.4) | 1078(77.1) | 305(83.1) | |
| Gender | ||||
| Male, n(%) | 858(70.6) | 933(66.7) | 244(66.5) | 0.078 |
| Female, n(%) | 358(29.4) | 466(33.3) | 123(33.5) | |
| History of smoking, n(%) | 383(31.5) | 411(29.4) | 108(29.4) | 0.466 |
| History of alcoholism, n(%) | 51(4.2) | 65(4.6) | 18(4.9) | 0.792 |
| Laboratory examination | ||||
| Hcy, µmol/L | 16.55 ± 7.42 | 16.52 ± 7.19 | 16.49 ± 6.66 | 0.986 |
| TG, mmol/L | 1.85 ± 1.62 | 1.81 ± 1.57 | 1.80 ± 1.79 | 0.722 |
| TC, mmol/L | 4.93 ± 1.34 | 5.00 ± 1.35 | 5.04 ± 1.43 | 0.253 |
| HDL-C, mmol/L | 1.24 ± 0.35 | 1.29 ± 0.39 | 1.28 ± 0.37 | 0.007 |
| LDL-C, mmol/L | 2.78 ± 0.97 | 2.81 ± 0.97 | 2.86 ± 1.03 | 0.420 |